STOCK TITAN

D. E. Shaw group discloses 3.9% Keros Therapeutics (KROS) ownership in 13G/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Keros Therapeutics, Inc. received an updated ownership filing from D. E. Shaw entities and David E. Shaw. As of December 31, 2025, they report beneficial ownership of 756,156 shares of common stock, representing 3.9% of the outstanding shares.

The filing shows no sole voting or dispositive power; all authority over these shares is shared through various D. E. Shaw investment vehicles. David E. Shaw may be deemed a beneficial owner through his control of related entities but expressly disclaims beneficial ownership. The reporting persons also certify the shares are not held to change or influence control of Keros.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



D. E. Shaw & Co., L.P.
Signature:/s/ Daniel R. Marcus
Name/Title:Daniel R. Marcus / Chief Compliance Officer
Date:02/17/2026
D. E. Shaw & Co., L.L.C.
Signature:/s/ Daniel R. Marcus
Name/Title:Daniel R. Marcus / Authorized Signatory
Date:02/17/2026
David E. Shaw
Signature:/s/ Daniel R. Marcus
Name/Title:Daniel R. Marcus / Attorney-in-Fact for David E. Shaw
Date:02/17/2026

Comments accompanying signature: Exhibit 1: Power of Attorney, granted by David E. Shaw relating to D. E. Shaw & Co., Inc., in favor of the signatories hereto, among others, dated August 1, 2024. Exhibit 2: Power of Attorney, granted by David E. Shaw relating to D. E. Shaw & Co. II, Inc., in favor of the signatories hereto, among others, dated August 1, 2024.
Exhibit Information

Exhibit 3: Joint Filing Agreement, by and among the Reporting Persons, dated February 17, 2026.

FAQ

What percentage of Keros Therapeutics (KROS) does D. E. Shaw report owning?

D. E. Shaw entities and David E. Shaw report beneficial ownership of 3.9% of Keros Therapeutics’ common stock. This corresponds to 756,156 shares as of December 31, 2025, according to the amended Schedule 13G/A filing.

How many Keros Therapeutics (KROS) shares are beneficially owned by D. E. Shaw?

The filing reports beneficial ownership of 756,156 Keros Therapeutics common shares. These are held through several D. E. Shaw investment vehicles, including Valence, Oculus, Composite Portfolios, and accounts managed by D. E. Shaw Investment Management.

Does David E. Shaw directly own Keros Therapeutics (KROS) shares?

The filing states that David E. Shaw does not own any shares directly. He may be deemed to beneficially own 756,156 shares through his control of various D. E. Shaw entities, but he disclaims beneficial ownership of those shares.

What voting power does D. E. Shaw have over Keros Therapeutics (KROS) shares?

The reporting persons indicate no sole voting power over Keros shares. They report shared voting power over up to 756,156 shares and similarly shared dispositive power, reflecting control exercised through multiple affiliated investment entities.

Is D. E. Shaw seeking to influence control of Keros Therapeutics (KROS)?

The reporting persons certify the Keros shares were not acquired and are not held for the purpose of changing or influencing control of the company. They also state the holdings are not part of any control-related transaction, aside from limited proxy nomination activities.

Which entities are included in the Keros Therapeutics (KROS) Schedule 13G/A by D. E. Shaw?

The filing lists D. E. Shaw & Co., L.P., D. E. Shaw & Co., L.L.C., and David E. Shaw as reporting persons. Underlying positions are held by Valence, Oculus, Composite Portfolios, and accounts managed by D. E. Shaw Investment Management.
Keros Therapeutics, Inc.

NASDAQ:KROS

KROS Rankings

KROS Latest News

KROS Latest SEC Filings

KROS Stock Data

505.13M
28.54M
Biotechnology
Pharmaceutical Preparations
Link
United States
LEXINGTON